DIA513.06+3.70 0.73%
SPY741.75+3.99 0.54%
QQQ721.34+4.22 0.59%

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Barchart·04/08/2026 06:47:00
Listen to the news

Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease

According to patient accounts, multiple critically ill patients with very poor prognoses reported meaningful improvements in functional status, appetite, mobility, and overall condition after taking the Company's product

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

Contact Us

Contact Number :+852 3852 8500
Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hk
Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hk
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2026 Webull Securities Limited. All rights reserved.